ArticleJournal of immunology (Baltimore, Md. : 1950)2008
Targeting of myelin protein zero in a spontaneous autoimmune polyneuropathy.
Article in Journal of immunology (Baltimore, Md. : 1950), 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 43 citations in OpenAlex.
- A recombinant IgG1 Fc-domain protein ameliorates inflammatory demyelinating peripheral neuropathy.Frontiers in immunology · 2026Article
- Animal models of immune-mediated demyelinating polyneuropathies.Autoimmunity · 2024Review
- How inflammation dictates diabetic peripheral neuropathy: An enlightening review.CNS neuroscience & therapeutics · 2024Review
- Cytokine Gene Polymorphisms in Patients with Chronic Inflammatory Demyelinating Polyneuropathy.Cells · 2023Article
- Immune-Mediated Neuropathies: Pathophysiology and Management.International journal of molecular sciences · 2023Review
- The immune response and aging in chronic inflammatory demyelinating polyradiculoneuropathy.Journal of neuroinflammation · 2021Review
- Serum CXCL13 reflects local B-cell mediated inflammatory demyelinating peripheral neuropathy.Scientific reports · 2019Article
- Elimination of activating Fcγ receptors in spontaneous autoimmune peripheral polyneuropathy model protects from neuropathic disease.PloS one · 2019Article
- Schwann cell-derived periostin promotes autoimmune peripheral polyneuropathy via macrophage recruitment.The Journal of clinical investigation · 2018Article
- Novel pathomechanisms in inflammatory neuropathies.Journal of neuroinflammation · 2017Review
- Regulatory T and B lymphocytes in a spontaneous autoimmune polyneuropathy.Clinical and experimental immunology · 2016Article
- AAV1.NT-3 gene therapy attenuates spontaneous autoimmune peripheral polyneuropathy.Gene therapy · 2016Article
- Inflammatory neuropathies: pathology, molecular markers and targets for specific therapeutic intervention.Acta neuropathologica · 2015Review
- Impaired dendritic cell function in a spontaneous autoimmune polyneuropathy.Journal of immunology (Baltimore, Md. : 1950) · 2015Article
- VIP-expressing dendritic cells protect against spontaneous autoimmune peripheral polyneuropathy.Molecular therapy : the journal of the American Society of Gene Therapy · 2014Article
- Molecules involved in the crosstalk between immune- and peripheral nerve Schwann cells.Journal of clinical immunology · 2014Review
- Interleukin-17 impedes Schwann cell-mediated myelination.Journal of neuroinflammation · 2014Article
- Inflammation: therapeutic targets for diabetic neuropathy.Molecular neurobiology · 2014Review
- CD19 as a therapeutic target in a spontaneous autoimmune polyneuropathy.Clinical and experimental immunology · 2014Article
- Animal models of autoimmune neuropathy.ILAR journal · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Elimination of the costimulatory molecule B7-2 prevents autoimmune diabetes in NOD mice, but leads to the development of a spontaneous autoimmune polyneuropathy (SAP), which resembles the human disease chronic inflammatory demyelinating polyneuropathy (CIDP). In this study, we examined the immunopathogenic mechanisms in this model, including identification of SAP Ags. We found that B7-2-deficient NOD mice exhibit changes in cytokine and chemokine gene expression in spleens over time. There was an increase in IL-17 and a decrease in IL-10 transcript levels at 4 mo (preclinical phase), whereas IFN-gamma expression peaked at 8 mo (clinical phase). There was also an increase in transcript levels of Th1 cytokines, CXCL10, and RANTES in sciatic nerves of mice that developed SAP. Splenocytes from SAP mice exhibited proliferative and Th1 cytokine responses to myelin P0 (180-199), but not to other P0 peptides or P2 (53-78). Adoptive transfer of P0-reactive T cells generated from SAP mice induced neuropathy in four of six NOD.SCID mice. Data from i.v. tolerance studies indicate that myelin P0 is one of the autoantigens targeted by T cells in SAP in this model. The expression of P0 by peri-islet Schwann cells provides a potential mechanism linking islet autoimmunity and inflammatory neuropathy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.